EDS Formulations Suppress Breast Cancer in Pre-Trial Testing

EDS Formulations Suppress Breast Cancer in Pre-Trial Testing

Baltimore, MD., September 28, 201b /PRNewswire/ — Epigenetic Data Sciences’ (EDS) new pre-trial results could pave the way for gene targeted treatment options for the estimated 1.7 million women worldwide who are living with breast cancer[1]. In EDS’s first ever study, their Breast Cancer formulations were tested against the MDA-MB-231 human breast cancer cell line, commonly known as triple-negative breast cancer (TNBC). This cell line is highly aggressive and invasive, with no targeted therapies for these tumors currently on the market.[2]

These formulations were created to combat key genes involved in the formation and progression of these cells, while also enhancing the body’s immune system to detect and fight back against the cells naturally. Preliminary results showed up to a 93% decrease in cells after exposure to EDS formulations in a 96-hour period.

Control and Treated plates after 96 hours

The findings of the study provide pre-clinical evidence for intravenous and oral treatment options.

“The findings from this study have important implications for women living with breast cancer,” said Andrew Pollack, CEO of Epigenetic Data Sciences. “We found our Breast Cancer formulations to be highly effective, and look forward to the next phase of our trials.”

Study Findings

A pre-clinical trial with 20 mice (divided evenly into a treated and control group were implanted with human breast cancer cells. After a treatment schedule lasting 36 days, preliminary findings demonstrate significant reduction in tumor growth versus control. Treated mice showed a mean tumor size 52% below those measured in the controls. Further study will look at metastasis rates to major organs.

About Epigenetic Data Sciences
With work beginning in 2014, Epigenetic Data Sciences is leading the fight against disease with cutting edge technologies through multiple disciplines. EDS is a pioneer in combining systems biology, epigenetics, and data science to study the abnormal gene expression critical for disease formation and progression. This knowledge is key to formulating plans to counter this dysregulation. With the Cancer and Neuro-Aging divisions up and running, EDS is on a mission to help those living with disease feel more confident in their self-care. For more information about EDS visit EpigeneticDS.com or follow us on social media – Twitter, LinkedIn, Facebook and YouTube.

[1] https://www.bcrf.org/breast-cancer-statistics

[2] https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf